candesartan cilexetil / Generic mfg. - LARVOL DELTA

EFFICACY ANALYSIS OF MONOTHERAPY WITH TELITACICEPT IN IMMUNOGLOBULIN A NEPHROPATHY PATIENTS AT HIGH PROGRESSION RISK (ISN-WCN 2026) - "She was initially treated with oral prednisone 30mg daily and a full dose of candesartan. Meanwhile, it avoids the use of hormones and corresponding side effects, making it worthy of clinical recommendation. However, due to the small number of cases, further clinical verification is required."

Clinical • Monotherapy • Glomerulonephritis • IgA Nephropathy • Renal Disease

High-performance thin-layer chromatographic method for simultaneous determination of some Angiotensin II Receptor Antagonists with amlodipine in spiked human plasma with UV detection. (PubMed, BMC Chem) - "A simple, sensitive, precise, and cost-effective high-performance thin-layer chromatographic method has been developed and validated for the simultaneous determination of Amlodipine and some Angiotensin II Receptor Antagonist drugs, including Olmesartan, Telmisartan, Candesartan, Losartan, and Irbesartan, in spiked human plasma. Amlodipine and the investigated Angiotensin II Receptor Antagonist drugs were successfully detected and quantified in both bulk drug and plasma samples, yielding high recovery percentages and low standard deviation values. The greenness of the proposed HPTLC method has been evaluated using the standards of greenness profile (AGREE and GAPI) and Eco-Scale."

Journal

Cancer Therapy-Related Cardiac Dysfunction in Breast Cancer Patients Receiving Combination Therapy of Candesartan and Carvedilol for Primary Prevention: A Prospective Longitudinal Study. (PubMed, J Korean Med Sci) - "In a primary prevention strategy with combined therapy of candesartan and carvedilol, asymptomatic CTRCD was still not uncommon and hypertension was a strong risk factor of CTRCD in breast cancer patients treated with cardiotoxic cancer therapy."

Journal • Observational data • Breast Cancer • Cardiovascular • Hypertension • Oncology • Solid Tumor

DOSE-RESPONSE NETWORK META-ANALYSIS OF PHARMACOLOGICAL CARDIOPROTECTION DURING CHEMOTHERAPY IN PATIENTS WITH BREAST CANCER: A COMPREHENSIVE BAYESIAN HIERARCHICAL ANALYSIS AND NETWORK META-REGRESSION WITH MACHINE LEARNING INTEGRATION. (ACC 2026) - "Candesartan ranked highest (SUCRA=0.736), followed by Carvedilol (SUCRA=0.685) and Spironolactone (SUCRA=0.634). Treatments show potential cardioprotection during chemotherapy, but none achieved clinically meaningful LVEF preservation. Candesartan ranked highest, though modest effects highlight the need for optimized, personalized dosing"

Machine learning • Retrospective data • Breast Cancer • Diabetes • Hypertension • Metabolic Disorders • Oncology • Solid Tumor

Candesartan cilexetil disrupts methicillin-resistant Staphylococcus aureus membrane and potentiates gentamicin and polymyxin B activity. (PubMed, Nat Commun) - "Structural activity relationship analysis shows that the tetrazole ring and ester carbonic acid of CC are critical for antibacterial activity. Finally, CC reduces MRSA-MW2 replication in a murine MRSA abscess model, supporting a potential role of CC as a lead antimicrobial compound/potentiator against MRSA."

Journal • Infectious Disease

The Candesartan Adjunctive Depression Trials-CADET: Study Protocols for Double-Blind, Randomized, Placebo-Controlled Trials for Bipolar Depression and Major Depressive Disorder. (PubMed, J Clin Psychopharmacol) - "The CADET Trials examine the efficacy of candesartan in reducing depressive symptoms in both unipolar and bipolar depression, and whether its effects are mediated through the renin-angiotensin system. Candesartan is affordable, accessible, and well-tolerated. If effective, it could quickly be adopted into clinical practice as a new adjunctive medication for the treatment of these disorders."

Journal • Bipolar Disorder • Cardiovascular • CNS Disorders • Depression • Hypertension • Inflammation • Major Depressive Disorder • Mood Disorders • Psychiatry

The angiotensin II receptor blocker candesartan mitigates cisplatin-induced myocardial injury via suppression of TLR-4/NF-κB/IRF-3/AP-1 signaling and restoration of antioxidant defenses. (PubMed, Tissue Cell) - "These findings highlight CAN as a promising adjunct to alleviate CIS-induced cardiotoxicity and preserve cardiovascular health in cancer patients undergoing CIS chemotherapy. However, further investigations and clinical trials are needed to validate these preclinical data."

Journal • Cardiovascular • Inflammation • Oncology • FOS • JUN • TLR4

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P3 | N=10000 | Recruiting | Sponsor: UMC Utrecht | Phase classification: P4 ➔ P3 | N=7100 ➔ 10000 | Trial completion date: Dec 2023 ➔ Dec 2025 | Trial primary completion date: Dec 2021 ➔ Dec 2023

Enrollment change • Phase classification • Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P4 | N=6800 | Recruiting | Sponsor: MJM Bonten | N=4000 ➔ 6800 | Trial completion date: Feb 2019 ➔ Jun 2022 | Trial primary completion date: Feb 2019 ➔ Dec 2021 | Initiation date: Dec 2015 ➔ Apr 2016

Enrollment change • Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P4 | N=7100 | Recruiting | Sponsor: MJM Bonten | Trial completion date: Jun 2022 ➔ Dec 2023

Trial completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P4 | N=4000 | Recruiting | Sponsor: UMC Utrecht

New P4 trial • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P3 | N=10000 | Recruiting | Sponsor: UMC Utrecht | Trial completion date: Dec 2025 ➔ Feb 2028 | Trial primary completion date: Dec 2023 ➔ Feb 2026

Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P3 | N=20000 | Recruiting | Sponsor: UMC Utrecht | N=10000 ➔ 20000

Enrollment change • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Surgically-Repaired Bartonella Pulmonic Valve Endocarditis-Associated Glomerulonephritis: Nephritic Remission, Nephrotic Sequelae (NKF-SCM 2026) - "She was earlier treated as urinary tract infection with clindamycin and cefpodoxime...Oral prednisone was started...RESULTS/CASE DISCUSSION The case shows the importance of: 1) Bartonella as an important cause of IE-associated GN; 2) the utility of 18F-FDG PET/CT scan to diagnose IE; 3) Potential for residual proteinuria in cases of surgically corrected IE-associated GN. CONCLUSION Despite surgery and early Nephritic and AKI resolution, Four months later, sCr is 0.8 mg/dL, no hematuria but UPCR is still 3.6 g/g despite candesartan."

Clinical • Acute Kidney Injury • Cardiovascular • Glomerulonephritis • Infectious Disease • Lupus Nephritis • Nephrology • Renal Disease

A Retrospective Analysis of Human Angiotensin II Receptor Blockers (ARB) Pharmacokinetics, Dosages and Cmax Values for the Experimental Modelling of Pleiotropic and Supratherapeutic Activities. (PubMed, Basic Clin Pharmacol Toxicol) - "Our findings suggest that Cmax is variable and heterogeneous between ARBs, with upper range values as high as 13.6 micromolar in the case of valsartan and lower range values as low as 0.4 micromolar for candesartan. We propose that modelling of ARB pleiotropy be conducted at these concentrations, whereas higher concentrations will mimic supratherapeutic applications."

Journal • PK/PD data • Retrospective data • Alzheimer's Disease • Chronic Obstructive Pulmonary Disease • CNS Disorders • Diabetes • Immunology • Metabolic Disorders • Muscular Dystrophy • Pulmonary Disease • Respiratory Diseases

AIFA-CARDIO-129: Pharmacological optimization in prevention in Heart Failure: A Sex-gap? (clinicaltrialsregister.eu) - P4 | N=368 | Not yet recruiting | Sponsor: Policlinico San Donato S.p.A.

New P4 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

Unique gut microbiota and metabolomic profiling as biomarker of post-transplant recovery in acute-on-chronic liver failure after liver transplantation. (PubMed, Appl Microbiol Biotechnol) - "Metabolomic analysis revealed substantial differences, including enrichment of tangeritin and depletion of candesartan in the ACLF group...This study offers valuable insights for further investigation into the pathogenesis and post-LT prognosis. KEY POINTS: • ACLF patients have a unique gut microbiota and metabolic profile after LT • g__Anaerostipes is the prominent biomarker of ACLF's multi-omics signature • g__Lachnoclostridium is a promising indicator of recovery after LT."

Biomarker • Journal • Fibrosis • Hepatocellular Cancer • Hepatology • Immunology • Liver Failure • Oncology • Solid Tumor • Transplantation

Superior outcomes of candesartan over topiramate in the treatment of migraine: A comparative cohort study. (PubMed, Cephalalgia) - "These findings were confirmed in the sensitivity analysis using optimal matching.ConclusionsCandesartan demonstrates a favorable tolerability and effectiveness profile compared to topiramate. Therefore, (inter)national treatment guidelines for migraine prevention should be revised to spare patients from being prescribed medications that have a low tolerability profile, as demonstrated by this study."

Journal • CNS Disorders • Migraine • Pain

Candesartan cilexetil as a repurposed therapeutic candidate for nasopharyngeal carcinoma: Integrated in vitro and in silico analyses. (PubMed, EXCLI J) - "See also the graphical abstract(Fig. 1)."

Journal • Preclinical • Cardiovascular • Hypertension • Nasopharyngeal Carcinoma • Oncology • Solid Tumor • SNAI2 • VIM

E. CandClus2 V3: Episodic CandClus2: A randomized, placebo-controlled, triple blind study of candesartan in adults with episodic cluster headache (clinicaltrialsregister.eu) - P2/3 | N=83 | Not yet recruiting | Sponsor: Helse Bergen HF, St. Olavs Hospital HF

New P2/3 trial • Pain

Chronic CandClus2 V1: Chronic CandClus2: A randomized, placebo-controlled, triple blind crossover study of candesartan in adults with chronic cluster headache (clinicaltrialsregister.eu) - P2/3 | N=44 | Not yet recruiting | Sponsor: Helse Bergen HF, St. Olavs Hospital HF

New P2/3 trial • Chronic Cluster Headache • Pain

NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients (clinicaltrials.gov) - P4 | N=2400 | Recruiting | Sponsor: Martin Huelsmann

New P4 trial • Cardiovascular • Diabetes • Heart Failure • Metabolic Disorders • Type 2 Diabetes Mellitus

NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients (clinicaltrials.gov) - P4 | N=2400 | Recruiting | Sponsor: Martin Huelsmann | Unknown status ➔ Recruiting | Trial completion date: Feb 2021 ➔ Dec 2026 | Trial primary completion date: Feb 2019 ➔ Dec 2025

Enrollment open • Trial completion date • Trial primary completion date • Cardiovascular • Diabetes • Heart Failure • Metabolic Disorders • Type 2 Diabetes Mellitus

ADIRAS: Changes After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor Type I (AT1) Blocker (clinicaltrials.gov) - P=N/A | N=35 | Recruiting | Sponsor: Slovak Academy of Sciences

Clinical • Hypertension

The effect of multidisciplinary open-label treatment in patients with persistent post-traumatic headache at two tertiary headache centers. (PubMed, Pain Manag) - P | "This prospective, non-randomized cohort study included consultations with a doctor, nurse, physiotherapist, and psychologist, and offered pharmacological treatment with candesartan, amitriptyline, or gabapentin. A comprehensive multidisciplinary program did not produce clinically meaningful improvement in headache or associated symptoms, although patient satisfaction remained high. Further research is needed to improve treatment strategies.Clinical trial registration: The ClinicalTrials.gov identifier is NCT05328635."

Journal • CNS Disorders • Depression • Insomnia • Pain • Psychiatry • Sleep Disorder • Vascular Neurology